124 related articles for article (PubMed ID: 36167530)
1. Liquid biopsy using ascitic fluid and pleural effusion supernatants for genomic profiling in gastrointestinal and lung cancers.
Wu H; Ji H; Yang W; Zhang M; Guo Y; Li B; Wang J; Chen R; Chen Y; Wang X
BMC Cancer; 2022 Sep; 22(1):1020. PubMed ID: 36167530
[TBL] [Abstract][Full Text] [Related]
2. Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer.
Tong L; Ding N; Tong X; Li J; Zhang Y; Wang X; Xu X; Ye M; Li C; Wu X; Bao H; Zhang X; Hong Q; Song Y; Shao YW; Bai C; Zhou J; Hu J
Theranostics; 2019; 9(19):5532-5541. PubMed ID: 31534501
[TBL] [Abstract][Full Text] [Related]
3. Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
Tu HY; Li YS; Bai XY; Sun YL; Zheng MY; Ke EE; Liao RQ; Jiang BY; Lin JX; Huang J; Xu BF; Yang JJ; Zhang XC; Zhou Q; Wang BC; Chen HJ; Tong X; Yu R; Wu X; Zhu D; Wu YL
Clin Lung Cancer; 2022 Mar; 23(2):135-142. PubMed ID: 34645582
[TBL] [Abstract][Full Text] [Related]
4. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
5. A multicenter real-world study of tumor-derived DNA from pleural effusion supernatant in genomic profiling of advanced lung cancer.
Jin S; Zhou C; Hou X; Fan Z; Zhao J; Ai X; Chu Y; Chen R; Guo R; Chen L
Transl Lung Cancer Res; 2020 Aug; 9(4):1507-1515. PubMed ID: 32953522
[TBL] [Abstract][Full Text] [Related]
6. Malignant pleural effusion supernatant is an alternative liquid biopsy specimen for comprehensive mutational profiling.
Guo Z; Xie Z; Shi H; Du W; Peng L; Han W; Duan F; Zhang X; Chen M; Duan J; Lin J; Chen X; Lizaso AA; Han-Zhang H; He J; Yin W
Thorac Cancer; 2019 Apr; 10(4):823-831. PubMed ID: 30779318
[TBL] [Abstract][Full Text] [Related]
7. Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing.
Yu Y; Qian J; Shen L; Ji W; Lu S
Int J Med Sci; 2021; 18(6):1510-1518. PubMed ID: 33628109
[TBL] [Abstract][Full Text] [Related]
8. Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions.
Villatoro S; Mayo-de-Las-Casas C; Jordana-Ariza N; Viteri-Ramírez S; Garzón-Ibañez M; Moya-Horno I; García-Peláez B; González-Cao M; Malapelle U; Balada-Bel A; Martínez-Bueno A; Campos R; Reguart N; Majem M; Blanco R; Blasco A; Catalán MJ; González X; Troncone G; Karachaliou N; Rosell R; Molina-Vila MA
Mol Oncol; 2019 Dec; 13(12):2633-2645. PubMed ID: 31529604
[TBL] [Abstract][Full Text] [Related]
9. Sensitive cell-free tumor DNA analysis in supernatant pleural effusions supports therapy selection and disease monitoring of lung cancer patients.
de Kock R; Knoops C; Baselmans M; Borne BVD; Brunsveld L; Scharnhorst V; Deiman B
Cancer Treat Res Commun; 2021; 29():100449. PubMed ID: 34481168
[TBL] [Abstract][Full Text] [Related]
10. Molecular Profiling for Supernatants and Matched Cell Pellets of Pleural Effusions in Non-Small-Cell Lung Cancer.
Xiang C; Huo M; Ma S; Guo L; Zhao R; Teng H; Zhang J; Han Y
J Mol Diagn; 2020 Apr; 22(4):513-522. PubMed ID: 32036088
[TBL] [Abstract][Full Text] [Related]
11. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of Genomic Alterations in Pericardial Effusion of Advanced Non-small Cell Lung Cancer.
He J; Hu X; Chen L; Liu Q; Jiang Y
Front Genet; 2022; 13():850290. PubMed ID: 35646096
[No Abstract] [Full Text] [Related]
13. Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine-needle aspiration specimens.
Hannigan B; Ye W; Mehrotra M; Lam V; Bolivar A; Zalles S; Barkoh BA; Duose D; Hu PC; Broaddus R; Stewart J; Heymach J; Medeiros LJ; Wistuba I; Luthra R; Roy-Chowdhuri S
Ann Oncol; 2019 Jun; 30(6):963-969. PubMed ID: 30887015
[TBL] [Abstract][Full Text] [Related]
14. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
Ma C; Yang X; Xing W; Yu H; Si T; Guo Z
Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608
[TBL] [Abstract][Full Text] [Related]
15. [The study of pleural effusion supernatant cell-free tumor DNA in tumor mutational burden assessment of advanced lung cancer].
Tong L; Ding N; Li JM; Xu XB; Zhang Y; Ye MS; Li C; Zhang X; Hong QY; Zhou J; Bai CX; Hu J
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Aug; 42(8):596-601. PubMed ID: 31378021
[No Abstract] [Full Text] [Related]
16. Cell-free DNA From Pleural Effusion Samples: Is It Right for Molecular Testing in Lung Adenocarcinoma?
Mokánszki A; Bádon ES; Mónus A; Tóth L; Bittner N; Méhes G
Pathol Oncol Res; 2021; 27():613071. PubMed ID: 34257581
[TBL] [Abstract][Full Text] [Related]
17. Detection of EGFR gene mutation status from pleural effusions and other body fluid specimens in patients with lung adenocarcinoma.
Zhang P; Wu X; Tang M; Nie X; Li L
Thorac Cancer; 2019 Dec; 10(12):2218-2224. PubMed ID: 31602787
[TBL] [Abstract][Full Text] [Related]
18. Pleural effusion supernatant: a reliable resource for cell-free DNA in molecular testing of lung cancer.
Thakur S; Rathor A; Jain S; Nambirajan A; Khurana S; Malik PS; Jain D
J Am Soc Cytopathol; 2024 Mar; ():. PubMed ID: 38704351
[TBL] [Abstract][Full Text] [Related]
19. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
